Drug intelligence / Profile preview

OB-25-02

Development stage: Preclinical
Lead developer: OCMS Bio
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

OB-25-02 is a preclinical-stage antibody-drug conjugate (ADC) being developed by OCMS Bio for the treatment of oncology indications. As an ADC, the molecule is designed to leverage the specificity of a monoclonal antibody to deliver a potent cytotoxic agent directly to tumor cells, thereby minimizing systemic toxicity and enhancing the therapeutic index. While the specific molecular target and the nature of the linker-payload system have not been publicly disclosed, the program is a key component of OCMS Bio's pipeline focused on developing next-generation targeted therapies for cancer.

Beyond the preview

Go deeper on OB-25-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OB-25-02.

Explore the full profile